Clinical Trial Update: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update comparing T-DM1 with tucatinib versus T-DM1 alone in preventing relapses in high-risk HER2-positive breast cancer; trial status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Kadcyla (ado-trastuzumab emtansine)
• Tukysa (tucatinib)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 3 | Status: ACTIVE_NOT_RECRUITING